series	seriesDescription	geoAreaCode	geoAreaName	timePeriodStart	value	time_detail	upperBound	lowerBound	basePeriod	source	footnotes	nature_code	nature_desc	units_code	units_desc	reportingType_code	reportingType_desc	value_detail	lowerBound_detail	upperBound_detail	level	parentCode	parentName	type	X	Y	ISO3	UN_Member	Country_Profile
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	2008.0	4.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	2009.0	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	2010.0	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	2011.0	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	2012.0	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	2013.0	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	2014.0	32.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	2015.0	38.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	2016.0	42.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	2017.0	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	2010.0	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	2011.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	2012.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	2013.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	2014.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	2015.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	2016.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	2017.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	Myanmar	2016.0	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	96.51752295	21.19332882	MMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	Myanmar	2017.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	96.51752295	21.19332882	MMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	2011.0	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	2012.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	2013.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	2014.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	2015.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	2016.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	2017.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	2010.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	2011.0	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	2012.0	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	2013.0	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	2014.0	25.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	2015.0	53.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	2016.0	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	2017.0	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	Cambodia	2015.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	104.922836	12.71163737	KHM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	Cambodia	2016.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	104.922836	12.71163737	KHM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	Cambodia	2017.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	104.922836	12.71163737	KHM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	Algeria	2016.0	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	2.678164227	28.15940032	DZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	Algeria	2017.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	2.678164227	28.15940032	DZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	2011.0	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	2012.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	2013.0	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	2014.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	2015.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	2016.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	2017.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	2008.0	42.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	2009.0	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	2010.0	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	2011.0	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	2012.0	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	2013.0	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	2014.0	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	2015.0	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	2016.0	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	2017.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	2008.0	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	2009.0	33.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	2010.0	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	2011.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	2012.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	2013.0	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	2014.0	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	2015.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	2016.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	2017.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	2011.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	2012.0	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	2013.0	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	2014.0	18.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	2015.0	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	2016.0	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	2017.0	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	2010.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	2011.0	15.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	2012.0	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	2013.0	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	2014.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	2015.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	2016.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	2017.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2011.0	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2012.0	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2013.0	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2014.0	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2015.0	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2016.0	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	2017.0	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	2009.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	2010.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	2011.0	5.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	2012.0	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	2013.0	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	2014.0	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	2015.0	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	2016.0	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	2017.0	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	2011.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	2012.0	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	2013.0	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	2014.0	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	2015.0	18.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	2016.0	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	2017.0	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	2008.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	2009.0	38.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	2010.0	38.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	2011.0	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	2012.0	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	2013.0	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	2014.0	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	2015.0	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	2016.0	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	2017.0	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	2011.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	2012.0	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	2013.0	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	2014.0	33.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	2015.0	33.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	2016.0	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	2017.0	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	2008.0	12.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	2009.0	18.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	2010.0	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	2011.0	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	2012.0	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	2013.0	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	2014.0	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	2015.0	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	2016.0	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	2017.0	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	2009.0	2.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	2010.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	2011.0	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	2012.0	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	2013.0	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	2014.0	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	2015.0	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	2016.0	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	2017.0	46.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	2011.0	54.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	2012.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	2013.0	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	2014.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	2015.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	2016.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	2017.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	2008.0	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	2009.0	18.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	2010.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	2011.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	2012.0	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	2013.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	2014.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	2015.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	2016.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	2017.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	2008.0	25.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	2009.0	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	2010.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	2011.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	2012.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	2013.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	2014.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	2015.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	2016.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	2017.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	2011.0	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	2012.0	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	2013.0	33.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	2014.0	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	2015.0	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	2016.0	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	2017.0	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	2010.0	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	2011.0	46.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	2012.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	2013.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	2014.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	2015.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	2016.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	2017.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	2012.0	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	2013.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	2014.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	2015.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	2016.0	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	2017.0	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	2009.0	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	2010.0	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	2011.0	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	2012.0	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	2013.0	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	2014.0	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	2015.0	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	2016.0	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	2017.0	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	2011.0	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	2012.0	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	2013.0	31.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	2014.0	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	2015.0	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	2016.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	2017.0	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	2009.0	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	2010.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	2011.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	2012.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	2013.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	2014.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	2015.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	2016.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	2017.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	2008.0	28.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	2009.0	34.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	2010.0	51.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	2011.0	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	2012.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	2013.0	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	2014.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	2015.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	2016.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	2017.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	Cyprus	2015.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	33.22285964	35.05659437	CYP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	Cyprus	2016.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	33.22285964	35.05659437	CYP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	Cyprus	2017.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	33.22285964	35.05659437	CYP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	2010.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	2011.0	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	2012.0	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	2013.0	29.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	2014.0	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	2015.0	62.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	2016.0	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	2017.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	2010.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	2011.0	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	2012.0	19.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	2013.0	32.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	2014.0	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	2015.0	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	2016.0	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	2017.0	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	Andorra	2014.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	1.576257417	42.54548611	AND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	Andorra	2015.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	1.576257417	42.54548611	AND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	Andorra	2016.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	1.576257417	42.54548611	AND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	Andorra	2017.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	1.576257417	42.54548611	AND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	2010.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	2011.0	12.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	2012.0	21.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	2013.0	34.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	2014.0	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	2015.0	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	2016.0	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	2017.0	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	2011.0	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	2012.0	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	2013.0	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	2014.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	2015.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	2016.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	2017.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	2009.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	2010.0	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	2011.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	2012.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	2013.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	2014.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	2015.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	2016.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	2017.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	2008.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	2009.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	2010.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	2011.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	2012.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	2013.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	2014.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	2015.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	2016.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	2017.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	Dominican Republic	2014.0	27.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-70.49847576	18.89832088	DOM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	Dominican Republic	2015.0	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-70.49847576	18.89832088	DOM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	Dominican Republic	2016.0	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-70.49847576	18.89832088	DOM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	Dominican Republic	2017.0	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-70.49847576	18.89832088	DOM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2010.0	17.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2011.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2012.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2013.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2014.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2015.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2016.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	2017.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	2010.0	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	2011.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	2012.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	2013.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	2014.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	2015.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	2016.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	2017.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	2011.0	12.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	2012.0	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	2013.0	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	2014.0	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	2015.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	2016.0	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	2017.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	Eritrea	2016.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	38.11074289	16.12894644	ERI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	Eritrea	2017.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	38.11074289	16.12894644	ERI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	Angola	2013.0	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	17.57817062	-12.33724746	AGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	Angola	2014.0	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	17.57817062	-12.33724746	AGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	Angola	2015.0	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	17.57817062	-12.33724746	AGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	Angola	2016.0	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	17.57817062	-12.33724746	AGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	Angola	2017.0	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	17.57817062	-12.33724746	AGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	Fiji	2013.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	54	Melanesia	Country	177.9660884	-17.83301566	FJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	Fiji	2014.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	54	Melanesia	Country	177.9660884	-17.83301566	FJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	Fiji	2015.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	54	Melanesia	Country	177.9660884	-17.83301566	FJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	Fiji	2016.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	54	Melanesia	Country	177.9660884	-17.83301566	FJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	Fiji	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	54	Melanesia	Country	177.9660884	-17.83301566	FJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	2010.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	2011.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	2012.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	2013.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	2014.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	2015.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	2016.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	2017.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	2010.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	2011.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	2012.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	2013.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	2014.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	2015.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	2016.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	2017.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	Djibouti	2013.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	42.18274707	11.56004161	DJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	Djibouti	2014.0	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	42.18274707	11.56004161	DJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	Djibouti	2015.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	42.18274707	11.56004161	DJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	Djibouti	2016.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	42.18274707	11.56004161	DJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	Djibouti	2017.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	42.18274707	11.56004161	DJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	Georgia	2015.0	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	43.3713615	42.04813028	GEO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	Georgia	2016.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	43.3713615	42.04813028	GEO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	Georgia	2017.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	43.3713615	42.04813028	GEO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	2010.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	2011.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	2012.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	2013.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	2014.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	2015.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	2016.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	2017.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	2012.0	25.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	2013.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	2014.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	2015.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	2016.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	2008.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	2009.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	2010.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	2011.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	2012.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	2013.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	2014.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	2015.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	2016.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	2017.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	2012.0	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	2013.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	2014.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	2015.0	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	2016.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	2011.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	2012.0	2.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	2013.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	2014.0	12.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	2015.0	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	2016.0	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	2017.0	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	Kiribati	2013.0	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	-157.5643005	1.768837732	KIR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	Kiribati	2014.0	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	-157.5643005	1.768837732	KIR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	Kiribati	2015.0	74.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	-157.5643005	1.768837732	KIR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	Kiribati	2016.0	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	-157.5643005	1.768837732	KIR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	Kiribati	2017.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	-157.5643005	1.768837732	KIR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	2011.0	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	2012.0	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	2013.0	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	2014.0	5.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	2015.0	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	2016.0	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	2017.0	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	2012.0	32.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	2013.0	32.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	2014.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	2015.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	2016.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	2017.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	Azerbaijan	2014.0	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.01064725	40.39229544	AZE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	Azerbaijan	2015.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.01064725	40.39229544	AZE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	Azerbaijan	2016.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.01064725	40.39229544	AZE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	Azerbaijan	2017.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.01064725	40.39229544	AZE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	2012.0	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	2013.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	2014.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	2015.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	2016.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	2017.0	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	Guatemala	2013.0	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-91.2312746	15.00273719	GTM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	Guatemala	2014.0	51.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-91.2312746	15.00273719	GTM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	Guatemala	2015.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-91.2312746	15.00273719	GTM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	Guatemala	2016.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-91.2312746	15.00273719	GTM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	Guatemala	2017.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-91.2312746	15.00273719	GTM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	2011.0	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	2012.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	2013.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	2014.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	2015.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	2016.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	2017.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	2011.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	2012.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	2013.0	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	2014.0	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	2015.0	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	2016.0	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	2017.0	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	2011.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	2012.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	2013.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	2014.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	2015.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	2016.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	2017.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	2011.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	2012.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	2013.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	2014.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	2015.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	2016.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	2011.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	2012.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	2013.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	2014.0	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	2015.0	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	2016.0	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	2017.0	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	2012.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	2013.0	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	2014.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	2015.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	2016.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	2017.0	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	2008.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	2009.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	2010.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	2011.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	2012.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	2013.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	2014.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	2015.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	2016.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	2017.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	368	Iraq	2017.0	33.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	43.76606267	33.05013795	IRQ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	2010.0	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	2011.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	2012.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	2013.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	2014.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	2015.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	2016.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	2017.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	2011.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	2012.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	2013.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	2014.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	2015.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	2016.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	2017.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	2008.0	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	2009.0	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	2010.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	2011.0	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	2012.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	2013.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	2014.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	2015.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	2016.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	2017.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	Cte d'Ivoire	2014.0	2.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-5.552690016	7.62211586	CIV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	Cte d'Ivoire	2015.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-5.552690016	7.62211586	CIV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	Cte d'Ivoire	2016.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-5.552690016	7.62211586	CIV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	Cte d'Ivoire	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-5.552690016	7.62211586	CIV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	2008.0	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	2009.0	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	2010.0	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	2011.0	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	2012.0	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	2013.0	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	2014.0	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	2015.0	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	2016.0	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	2017.0	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	2011.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	2012.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	2013.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	2014.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	2015.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	2016.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2012.0	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2013.0	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2014.0	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2015.0	74.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2016.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	2017.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	Afghanistan	2014.0	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	66.02688198	33.83160199	AFG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	Afghanistan	2015.0	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	66.02688198	33.83160199	AFG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	Afghanistan	2016.0	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	66.02688198	33.83160199	AFG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	Afghanistan	2017.0	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	66.02688198	33.83160199	AFG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	2011.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	2012.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	2013.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	2014.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	2015.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	2016.0	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	2017.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	Republic of Korea	2015.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	30	Eastern Asia	Country	127.8610254	36.45201023	KOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	Republic of Korea	2016.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	30	Eastern Asia	Country	127.8610254	36.45201023	KOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	Republic of Korea	2017.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	30	Eastern Asia	Country	127.8610254	36.45201023	KOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	2008.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	2009.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	2010.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	2011.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	2012.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	2013.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	2014.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	2015.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	2016.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	417	Kyrgyzstan	2017.0	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	143	Central Asia	Country	74.52324839	41.46204516	KGZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	Lao People's Democratic Republic	2014.0	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	101.9901968	20.27482773	LAO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	Lao People's Democratic Republic	2015.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	101.9901968	20.27482773	LAO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	Lao People's Democratic Republic	2016.0	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	101.9901968	20.27482773	LAO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	Lao People's Democratic Republic	2017.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	101.9901968	20.27482773	LAO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	2008.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	2009.0	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	2010.0	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	2011.0	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	2012.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	2013.0	74.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	2014.0	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	2015.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	2016.0	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	2017.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	422	Lebanon	2017.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.89391711	33.92152458	LBN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	Lesotho	2015.0	29.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	28.25362195	-29.58041814	LSO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	Lesotho	2016.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	28.25362195	-29.58041814	LSO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	Lesotho	2017.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	28.25362195	-29.58041814	LSO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	2011.0	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	2012.0	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	2013.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	2014.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	2015.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	2016.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	2017.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	Liberia	2014.0	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-9.311879038	6.448381009	LBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	Liberia	2015.0	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-9.311879038	6.448381009	LBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	Liberia	2016.0	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-9.311879038	6.448381009	LBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	Liberia	2017.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-9.311879038	6.448381009	LBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432		2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432		2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432		2010.0	2.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432		2011.0	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432		2012.0	21.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432		2013.0	27.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432		2014.0	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432		2015.0	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432		2016.0	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432		2017.0	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	Libya	2014.0	39.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	18.0295985	27.04042819	LBY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	Libya	2015.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	18.0295985	27.04042819	LBY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	Libya	2016.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	18.0295985	27.04042819	LBY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	Libya	2017.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	18.0295985	27.04042819	LBY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	2009.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	2010.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	2011.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	2012.0	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	2013.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	2014.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	2015.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	2016.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	2017.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	Lithuania	2016.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	23.90517807	55.33680309	LTU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	Lithuania	2017.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	23.90517807	55.33680309	LTU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	2008.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	2009.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	2010.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	2011.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	2012.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	2013.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	2014.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	2015.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	2016.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	2017.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	Madagascar	2013.0	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	46.6982339	-19.38514785	MDG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	Madagascar	2014.0	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	46.6982339	-19.38514785	MDG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	Madagascar	2015.0	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	46.6982339	-19.38514785	MDG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	Madagascar	2016.0	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	46.6982339	-19.38514785	MDG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	Madagascar	2017.0	74.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	46.6982339	-19.38514785	MDG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	2012.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	2013.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	2014.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	2015.0	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	2016.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	2017.0	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	2011.0	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	2012.0	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	2013.0	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	2014.0	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	2015.0	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	2016.0	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	2017.0	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	Mauritania	2013.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-10.33187259	20.26089546	MRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	Mauritania	2014.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-10.33187259	20.26089546	MRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	Mauritania	2015.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-10.33187259	20.26089546	MRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	Mauritania	2016.0	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-10.33187259	20.26089546	MRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	Mauritania	2017.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-10.33187259	20.26089546	MRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	2008.0	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	2009.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	2010.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	2011.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	2012.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	2013.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	2014.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	2015.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	2016.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	2017.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	Mauritius	2016.0	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	57.568022	-20.28581998	MUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	Mauritius	2017.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	57.568022	-20.28581998	MUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	2008.0	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	2009.0	46.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	2010.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	2011.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	2012.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	2013.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	2014.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	2015.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	2016.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	2017.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	2008.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	2009.0	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	2010.0	42.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	2011.0	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	2012.0	54.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	2013.0	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	2014.0	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	2015.0	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	2016.0	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	2017.0	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	496	Mongolia	2017.0	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	30	Eastern Asia	Country	103.0728057	46.83892054	MNG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	Republic of Moldova	2013.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	28.4650624	47.20236795	MDA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	Republic of Moldova	2014.0	28.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	28.4650624	47.20236795	MDA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	Republic of Moldova	2015.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	28.4650624	47.20236795	MDA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	Republic of Moldova	2016.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	28.4650624	47.20236795	MDA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	Republic of Moldova	2017.0	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	28.4650624	47.20236795	MDA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	2009.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	2010.0	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	2011.0	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	2012.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	2013.0	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	2014.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	2015.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	2016.0	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	2017.0	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	Bangladesh	2015.0	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	89.17660788	22.86961622	BGD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	Bangladesh	2016.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	89.17660788	22.86961622	BGD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	Bangladesh	2017.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	89.17660788	22.86961622	BGD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	2010.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	2011.0	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	2012.0	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	2013.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	2014.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	2015.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	2016.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	Mozambique	2013.0	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	38.18479941	-14.27963886	MOZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	Mozambique	2014.0	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	38.18479941	-14.27963886	MOZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	Mozambique	2015.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	38.18479941	-14.27963886	MOZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	Mozambique	2016.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	38.18479941	-14.27963886	MOZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	Mozambique	2017.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	38.18479941	-14.27963886	MOZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	Armenia	2015.0	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.93839317	40.29499741	ARM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	Armenia	2016.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.93839317	40.29499741	ARM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	Armenia	2017.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.93839317	40.29499741	ARM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	2009.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	2010.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	2011.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	2012.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	2013.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	2014.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	2015.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	2016.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	2008.0	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	2009.0	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	2010.0	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	2011.0	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	2012.0	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	2013.0	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	2014.0	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	2015.0	62.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	2016.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	2017.0	74.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	2008.0	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	2009.0	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	2010.0	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	2011.0	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	2012.0	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	2013.0	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	2014.0	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	2015.0	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	2016.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	2017.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	2009.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	2010.0	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	2011.0	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	2012.0	15.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	2013.0	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	2014.0	28.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	2015.0	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	2016.0	39.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	2017.0	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	Namibia	2015.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	17.21907885	-22.13817068	NAM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	Namibia	2016.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	17.21907885	-22.13817068	NAM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	Namibia	2017.0	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	17.21907885	-22.13817068	NAM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	2011.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	2012.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	2013.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	2014.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	2015.0	2.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	2016.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	2017.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	2009.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	2010.0	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	2011.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	2012.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	2013.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	2014.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	2015.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	2016.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	2017.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	Nepal	2015.0	5.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	83.94678863	28.25866332	NPL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	Nepal	2016.0	46.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	83.94678863	28.25866332	NPL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	Nepal	2017.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	83.94678863	28.25866332	NPL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	2009.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	2010.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	2011.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	2012.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	2013.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	2014.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	2015.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	2016.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	2017.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	2008.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	2009.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	2010.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	2011.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	2012.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	2013.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	2014.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	2015.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	2016.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	2017.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	2011.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	2012.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	2013.0	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	2014.0	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	2015.0	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	2016.0	29.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	2017.0	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	2010.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	2011.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	2012.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	2013.0	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	2014.0	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	2015.0	27.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	2016.0	29.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	2017.0	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	2009.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	2010.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	2011.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	2012.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	2013.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	2014.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	2015.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	2016.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	2017.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	2011.0	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	2012.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	2013.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	2014.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	2015.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	2016.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	2017.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	2012.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	2013.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	2014.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	2015.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	2016.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	2017.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	Niger	2014.0	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	9.400167877	17.42143036	NER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	Niger	2015.0	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	9.400167877	17.42143036	NER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	Niger	2016.0	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	9.400167877	17.42143036	NER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	Niger	2017.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	9.400167877	17.42143036	NER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	Nigeria	2015.0	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	8.097363256	9.585789025	NGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	Nigeria	2016.0	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	8.097363256	9.585789025	NGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	Nigeria	2017.0	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	8.097363256	9.585789025	NGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	2009.0	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	2010.0	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	2011.0	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	2012.0	32.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	2013.0	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	2014.0	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	2015.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	2016.0	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	2017.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	2009.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	2010.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	2011.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	2012.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	2013.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	2014.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	2015.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	2016.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	2008.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	2009.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	2010.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	2011.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	2012.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	2013.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	2014.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	2015.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	2016.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	2017.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	2010.0	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	2011.0	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	2012.0	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	2013.0	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	2014.0	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	2015.0	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	2016.0	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	2017.0	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	2009.0	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	2010.0	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	2011.0	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	2012.0	46.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	2013.0	38.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	2014.0	29.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	2015.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	2016.0	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	2017.0	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	2008.0	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	2009.0	18.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	2010.0	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	2011.0	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	2012.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	2013.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	2014.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	2015.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	2016.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	2017.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	Pakistan	2013.0	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	68.80479684	29.36491634	PAK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	Pakistan	2014.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	68.80479684	29.36491634	PAK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	Pakistan	2015.0	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	68.80479684	29.36491634	PAK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	Pakistan	2016.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	68.80479684	29.36491634	PAK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	Pakistan	2017.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	34	Southern Asia	Country	68.80479684	29.36491634	PAK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	2010.0	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	2011.0	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	2012.0	62.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	2013.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	2014.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	2015.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	2016.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	2017.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	Papua New Guinea	2015.0	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	54	Melanesia	Country	145.8587761	-6.756057077	PNG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	Papua New Guinea	2016.0	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	54	Melanesia	Country	145.8587761	-6.756057077	PNG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	Papua New Guinea	2017.0	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	54	Melanesia	Country	145.8587761	-6.756057077	PNG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	2012.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	2013.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	2014.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	2015.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	2016.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	2017.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	2009.0	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	2010.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	2011.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	2012.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	2013.0	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	2014.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	2015.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	2016.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	2017.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	Philippines	2014.0	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	120.8601418	14.16591706	PHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	Philippines	2015.0	17.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	120.8601418	14.16591706	PHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	Philippines	2016.0	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	120.8601418	14.16591706	PHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	Philippines	2017.0	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	120.8601418	14.16591706	PHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	2011.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	2012.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	2013.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	2014.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	2015.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	2016.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	2017.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	2011.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	2012.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	2013.0	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	2014.0	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	2015.0	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	2016.0	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	2017.0	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	Portugal	2016.0	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	-7.961599811	39.68509315	PRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	Portugal	2017.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	-7.961599811	39.68509315	PRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	Guinea-Bissau	2015.0	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-14.40182514	12.11760394	GNB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	Guinea-Bissau	2016.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-14.40182514	12.11760394	GNB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	Guinea-Bissau	2017.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-14.40182514	12.11760394	GNB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	2009.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	2010.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	2011.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	2012.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	2013.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	2014.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	2015.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	2016.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	2017.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	Russian Federation	2016.0	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	99.01404926	61.61899849	RUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	Russian Federation	2017.0	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	99.01404926	61.61899849	RUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	2010.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	2011.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	2012.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	2013.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	2014.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	2015.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	2016.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	2017.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	San Marino	2016.0	53.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.46329038	43.93841766	SMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	San Marino	2017.0	53.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	12.46329038	43.93841766	SMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	Sao Tome and Principe	2013.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	6.609772265	0.241554875	STP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	Sao Tome and Principe	2014.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	6.609772265	0.241554875	STP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	Sao Tome and Principe	2015.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	6.609772265	0.241554875	STP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	Sao Tome and Principe	2016.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	6.609772265	0.241554875	STP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	Sao Tome and Principe	2017.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	17	Middle Africa	Country	6.609772265	0.241554875	STP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	Bolivia (Plurinational State of)	2014.0	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-64.66224284	-16.71273412	BOL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	Bolivia (Plurinational State of)	2015.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-64.66224284	-16.71273412	BOL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	Bolivia (Plurinational State of)	2016.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-64.66224284	-16.71273412	BOL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	Bolivia (Plurinational State of)	2017.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-64.66224284	-16.71273412	BOL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	2009.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	2010.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	2011.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	2012.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	2013.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	2014.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	2015.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	2016.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	2017.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	Senegal	2014.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-14.46636926	14.35920905	SEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	Senegal	2015.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-14.46636926	14.35920905	SEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	Senegal	2016.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-14.46636926	14.35920905	SEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	Senegal	2017.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-14.46636926	14.35920905	SEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	2011.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	2012.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	2013.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	2014.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	2015.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	2016.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	2017.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	2009.0	17.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	2010.0	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	2011.0	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	2012.0	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	2013.0	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	2014.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	2015.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	2016.0	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	2017.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	2009.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	2010.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	2011.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	2012.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	2013.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	2014.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	2015.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	2016.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	2017.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	Slovenia	2015.0	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	14.82209486	46.11958061	SVN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	Slovenia	2016.0	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	14.82209486	46.11958061	SVN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	Slovenia	2017.0	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	14.82209486	46.11958061	SVN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	2009.0	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	2010.0	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	2011.0	62.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	2012.0	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	2013.0	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	2014.0	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	2015.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	2016.0	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	2017.0	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	2012.0	21.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	2013.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	2014.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	2015.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	2016.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	2017.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	2012.0	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	2013.0	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	2014.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	2015.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	2016.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	2017.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722		2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722		2009.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722		2010.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722		2011.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722		2012.0	5.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722		2013.0	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722		2014.0	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722		2015.0	17.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722		2016.0	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722		2017.0	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global												
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	729	Sudan	2013.0	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	29.95650159	16.02643066	SDN	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	729	Sudan	2014.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	29.95650159	16.02643066	SDN	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	729	Sudan	2015.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	29.95650159	16.02643066	SDN	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	729	Sudan	2016.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	29.95650159	16.02643066	SDN	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	729	Sudan	2017.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	15	Northern Africa	Country	29.95650159	16.02643066	SDN	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	2010.0	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	2011.0	12.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	2012.0	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	2013.0	34.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	2014.0	51.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	2015.0	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	2016.0	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	2017.0	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	2011.0	4.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	2012.0	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	2013.0	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	2014.0	15.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	2015.0	17.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	2016.0	31.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	2017.0	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	2008.0	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	2009.0	19.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	2010.0	19.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	2011.0	25.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	2012.0	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	2013.0	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	2014.0	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	2015.0	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	2016.0	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	2017.0	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	Eswatini	2014.0	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	31.50149288	-26.56471011	SWZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	Eswatini	2015.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	31.50149288	-26.56471011	SWZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	Eswatini	2016.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	31.50149288	-26.56471011	SWZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	Eswatini	2017.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	18	Southern Africa	Country	31.50149288	-26.56471011	SWZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	2008.0	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	2009.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	2010.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	2011.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	2012.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	2013.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	2014.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	2015.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	2016.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	2017.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	2008.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	2009.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	2010.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	2011.0	4.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	2012.0	4.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	2013.0	4.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	2014.0	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	2015.0	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	2016.0	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	2017.0	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	2008.0	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	2009.0	25.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	2010.0	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	2011.0	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	2012.0	62.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	2013.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	2014.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	2015.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	2016.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	2017.0	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	2010.0	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	2011.0	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	2012.0	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	2013.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	2014.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	2015.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	2016.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	2017.0	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	Togo	2014.0	34.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	0.97835765	8.532096072	TGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	Togo	2015.0	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	0.97835765	8.532096072	TGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	Togo	2016.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	0.97835765	8.532096072	TGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	Togo	2017.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	0.97835765	8.532096072	TGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	2012.0	39.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	2013.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	2014.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	2015.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	2016.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	2017.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	2010.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	2011.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	2012.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	2013.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	2014.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	2015.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	2016.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	2017.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	2009.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	2010.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	2011.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	2012.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	2013.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	2014.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	2015.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	2016.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	2017.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	2011.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	2012.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	2013.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	2014.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	2015.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	2016.0	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	Uganda	2014.0	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	32.39100438	1.279557331	UGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	Uganda	2015.0	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	32.39100438	1.279557331	UGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	Uganda	2016.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	32.39100438	1.279557331	UGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	Uganda	2017.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	32.39100438	1.279557331	UGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	2010.0	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	2011.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	2012.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	2013.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	2014.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	2015.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	2016.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	2017.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	United Republic of Tanzania	2013.0	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	34.80521182	-6.265332606	TZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	United Republic of Tanzania	2014.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	34.80521182	-6.265332606	TZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	United Republic of Tanzania	2015.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	34.80521182	-6.265332606	TZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	United Republic of Tanzania	2016.0	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	34.80521182	-6.265332606	TZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	United Republic of Tanzania	2017.0	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	34.80521182	-6.265332606	TZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	2008.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	2009.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	2010.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	2011.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	2012.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	2013.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	2014.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	2015.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	2016.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	2017.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	Burkina Faso	2014.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-1.742843829	12.27491081	BFA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	Burkina Faso	2015.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-1.742843829	12.27491081	BFA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	Burkina Faso	2016.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-1.742843829	12.27491081	BFA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	Burkina Faso	2017.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	11	Western Africa	Country	-1.742843829	12.27491081	BFA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	2010.0	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	2011.0	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	2012.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	2013.0	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	2014.0	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	2015.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	2016.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	2017.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	Uzbekistan	2016.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	143	Central Asia	Country	63.11944558	41.77560518	UZB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	Uzbekistan	2017.0	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	143	Central Asia	Country	63.11944558	41.77560518	UZB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	Venezuela (Bolivarian Republic of)	2015.0	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-66.15642084	7.121324748	VEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	Venezuela (Bolivarian Republic of)	2016.0	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-66.15642084	7.121324748	VEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	Venezuela (Bolivarian Republic of)	2017.0	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	5	South America	Country	-66.15642084	7.121324748	VEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	2011.0	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	2012.0	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	2013.0	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	2014.0	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	2015.0	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	2016.0	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	2017.0	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	Zambia	2014.0	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	27.850329	-14.59701056	ZMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	Zambia	2015.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	27.850329	-14.59701056	ZMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	Zambia	2016.0	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	27.850329	-14.59701056	ZMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	Zambia	2017.0	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				5	14	Eastern Africa	Country	27.850329	-14.59701056	ZMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	2008.0	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	2009.0	53.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	2010.0	53.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	2011.0	54.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	2012.0	54.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	2013.0	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	2014.0	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	2015.0	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	2016.0	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	2017.0	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	Solomon Islands	2015.0	42.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	54	Melanesia	Country	160.1584117	-9.622391719	SLB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	Solomon Islands	2016.0	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	54	Melanesia	Country	160.1584117	-9.622391719	SLB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	Solomon Islands	2017.0	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global				4	54	Melanesia	Country	160.1584117	-9.622391719	SLB	1	1
